NASDAQ:KIN Kindred Biosciences (KIN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free KIN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.24▼$9.2650-Day Range$9.08▼$9.2552-Week Range$3.46▼$9.28Volume178,496 shsAverage Volume840,890 shsMarket Capitalization$420.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Kindred Biosciences alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Kindred Biosciences Stock (NASDAQ:KIN)Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details KIN Stock News HeadlinesApril 23, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”March 22, 2024 | mirror.co.ukTory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 23, 2024 | health.usnews.comKindred Hospital East GreensboroJanuary 22, 2024 | reuters.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | markets.businessinsider.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetDecember 17, 2023 | latimes.comHonoree: Nanxi LiuApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)November 8, 2023 | finance.yahoo.comGlobal Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%October 7, 2023 | health.usnews.comKindred Hospital-DaytonSeptember 21, 2023 | tmcnet.comBluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business developmentAugust 17, 2023 | bizjournals.comHow a small Peninsula company plans to take a big bite out of the pet drug marketJune 11, 2023 | es-us.finanzas.yahoo.comPet Cancer Therapeutics Global Market Report 2023May 11, 2023 | marketwatch.comOral COVID-19 Vaccine Market 2023 Expected Highest Growth and Precise Outlook | Pfizer, CanSino Biologics, Kindred BiosciencesMay 5, 2023 | marketwatch.comPet Medication Market Size and Forecast to 2031May 5, 2023 | health.usnews.comKindred Hospital-New Jersey Morris CountyApril 26, 2023 | uk.finance.yahoo.comVeterinary Dermatology Drugs Global Market Report 2023April 25, 2023 | health.usnews.comKindred Hospital Chicago-NorthlakeApril 19, 2023 | usnews.comKindred High SchoolApril 19, 2023 | thestreet.comKindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015March 31, 2023 | theguardian.comKindred review – a reductive, hollow view of Black traumaMarch 30, 2023 | marketwatch.comCanine Atopic Dermatitis Market Share and Forecast till 2031March 28, 2023 | health.usnews.comKindred Hospital-OntarioMarch 22, 2023 | marketwatch.comCompanion Animal Pharmaceuticals Market worth $19.6 billion | MarketsandMarketsMarch 7, 2023 | marketwatch.comThe Pet Medication study examines a number of direct and indirect factors that could affect the supply and demand dynamics in this marketMarch 6, 2023 | msn.comHow De La Soul's 3 Feet High and Rising broadened the possibilities of hip hopSee More Headlines Receive KIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KIN CUSIPN/A CIK1561743 Webkindredbio.com Phone(650) 701-7901FaxN/AEmployees63Year Founded2013Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,800,000.00 Net Margins-529.26% Pretax MarginN/A Return on Equity-54.19% Return on Assets-39.76% Debt Debt-to-Equity Ratio0.19 Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$42.16 million Price / Sales9.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.29Miscellaneous Outstanding Shares45,462,000Free FloatN/AMarket Cap$420.52 million OptionableOptionable Beta1.30 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesRichard H. ChinPresident, Chief Executive Officer & DirectorWendy WeeSecretary, Chief Financial & Accounting OfficerHangjun ZhanChief Scientific OfficerRussell RadefeldVP-Information Technology & Digital MarketingJay PetersonSenior Director-BiomanufacturingKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXAvid BioservicesNASDAQ:CDMOLarimar TherapeuticsNASDAQ:LRMRADC TherapeuticsNYSE:ADCTEntrada TherapeuticsNASDAQ:TRDAView All Competitors KIN Stock Analysis - Frequently Asked Questions How were Kindred Biosciences' earnings last quarter? Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX). This page (NASDAQ:KIN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kindred Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
